Cardio Diagnostics to Present AI Cardiovascular Risk Tools at Benefits Conferences

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will showcase its artificial intelligence-powered cardiovascular risk assessment solutions at four national benefits conferences in June. The company aims to engage employers, brokers, union trustees and plan administrators in strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses.

The company will present its Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform. These tools are designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes. The full press release is available at https://ibn.fm/qFRHu.

Cardiovascular disease remains the leading cause of death globally and a significant contributor to healthcare spending in the United States. By leveraging AI, Cardio Diagnostics aims to shift the paradigm from reactive treatment to proactive prevention. The company’s proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, or Core Technology, forms the basis of its clinical tests, which are intended to make cardiovascular disease prevention, detection and management more accessible and precise.

The conferences present an opportunity for the company to connect with key stakeholders who influence health plan design. Employers and union trustees are increasingly focused on managing healthcare costs while improving employee health outcomes. Cardio Diagnostics’ offerings could provide a data-driven approach to identifying high-risk individuals before costly events like heart attacks or strokes occur.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company. It was formed to further develop and commercialize clinical tests that leverage its Core Technology. The company aims to become a leading medical technology company for improving prevention, detection and treatment of cardiovascular disease.

For the latest news and updates relating to CDIO, visit the company’s newsroom at https://ibn.fm/CDIO. The company cautions that certain statements in this article are forward-looking and subject to risks and uncertainties as detailed in its filings with the SEC.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Cardio Diagnostics to Present AI Cardiovascular Risk Tools at Benefits Conferences.

The post Cardio Diagnostics to Present AI Cardiovascular Risk Tools at Benefits Conferences appeared first on citybuzz.